ReviewMini reviews in medicinal chemistry2026
A Comprehensive Review on Homology Modelling in Drug Development: Methodologies, Tools, and Evaluation.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Silico Drug Design and Discovery: Big Data for Small Molecule Design-2nd Edition.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The large accumulation of genomic and proteomic data has clearly established the need for accurate prediction of protein structure, especially with a view to enabling structurebased drug design. There are numerous ways to do this on computers these days, but one that distinctly stands out is homology modeling since it is fast, cheap, and consistent. It forecasts three-dimensional protein structures with unrecognized geometries by examining how they have evolved to date. This article provides an in-depth and up-to-date review of homology modeling. It addresses important steps, like discovering templates, sequence alignment, model building, loop refinement, side chain modeling, and structure validation. We have examined in detail the widely used tools, such as BLAST, MODELLER, Swiss-Model, SCWRL, PROCHECK, ProSA, and VERIFY3D. Also, it has been covered how artificial intelligence and machine learning can enhance these processes to be more precise, where little homology exists. Currently, a lot of focus is being placed on loop modeling problems, choosing a template, and structural validation procedures, like root mean square deviation (RMSD), Z-score, and Ramachandran plot statistics. In addition, we have examined how homology modeling is used in ligand docking and in lead optimization at the system level. The review offers great advice on how to speed up the drug-development process, especially for proteins that prove hard to crystallize or solve by X-ray crystallography. It does so by integrating concepts from bioinformatics, computational genomics, and structural biology into its design. We herein bridge traditional techniques and current computer technology to offer drug scientists a useful tool.
Indexed as
Identifiers
41863236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.